Intellego Technologies AB

Osakkeet
, ,
86

Kuvio tässä on sen että Sven on epäluuloinen ja uskoo että intellego on toimitusjohtajan huijausta. Normaali tilanteessa hänelle naurettaisiin mutta nyt hän on ruotsin talouslehtien toimittaja, jolla jokin verran luottamusta. Itse seuraan oheista discord kanavaa jossa erittäin kriittistä keskustelua eri ruotsalaisista yhtiöistä. Suurin osa harhaista salaliittoteoriaa mutta joskus jotain fiksuakin.

Itse luota intellegoon ja toimitusjohtajaan. Ja veikkaan että Nordeakin tehnyt kunnon taustatarkastukset.

1 tykkäys
87

Hyvä analyysi intellegosta bear, base ja bull arviot.

https://smallcaptreasures.substack.com/p/intellego-technologies-a-10-bagger?r=1od1d5&utm_campaign=post&utm_medium=web&triedRedirect=true

3 tykkäystä
88

Linkedin julkaistu eilen. "Not only is Intellego making progress on the disinfection front, but we are thrilled to announce our expanded partnership with one of the world’s largest companies in UV curing industry, which is now starting a global market launch of Intellego’s curing dosimeters and app system, UVAssure. "

https://www.linkedin.com/posts/intellego-tech_uvcuring-curingtechnology-uvdosimeter-activity-7259248584888397824-Smkn/?utm_source=share&utm_medium=member_desktop

4 tykkäystä
90

Toimitus Kiinaan EUR 2 miljoonaa. Ei mainintaa aikataulusta mutta voisi tulkita että loppuvuoden aikana. Lisäksi toimitetaan jollain luottolimitillä joka turvaa saatavat Intellegolle. Tämä uutta. Ilmeisesti Nordean kautta.
[Intellego Delivers UV Dosimeters Worth EUR 2 Million to Partner in Asia](https://Intellego Delivers UV Dosimeters Worth EUR 2 Million to Partner in Asia)

5 tykkäystä
91

Intellego aloittanut neuvottelut kansainvälisen jakelian kanssa. Testattu jo 18 kuukautta joten voisi olettaa että neuvottelut eivät kestä turhan pitkään. “Henkel” sopimuksen julkistusta odotellessa ihan hyviä tulevaisuuden näkymiä.

Intellego Technologies AB (publ) announces that it has entered into negotiations for a global distribution agreement for certain of its UV disinfection indicators and app system targeting the healthcare sector. Intellego was approached by one of the world’s largest suppliers of color indicators in the healthcare sector, a U.S.-based company with over 3,000 employees and a presence in more than 100 countries worldwide.
Over the past 18 months, the prospective partner has conducted a comprehensive evaluation of Intellego’s products and the broader UV dosimeter market, leading to a favorable assessment. The ongoing negotiations concern the global distribution rights for Intellego’s UVC dosimeters and app system, aimed at the healthcare market with an estimated annual value of approximately USD 1.6 billion

3 tykkäystä
95

Intellego and Likang expand collaboration with USD 360M, five-year deal in Asia

Tiedotteeseen suhteutettuna melko maltillinen kurssireaktio. Jännä nähdä kuinka lähtevät suorittamaan 2025 alkaen.

3 tykkäystä
96

Intellegon sivuilta vielä, eli diilin oletetaan alkavan loppuvuodesta 2025 ja kasvavan progressiivisesti.

Intellego and Likang expand collaboration with
USD 360M, five-year deal in Asia
Due to a positive reception of the dosimeter products, Intellego and Likang have agreed to
expand their collaboration to cover additional products in the disinfection industry in China and
Asia. Intellego grants the exclusive sales and marketing rights in China for a product used in
the disinfection market tied to minimum volumes totaling USD 360 million.
The deal is contingent on market approval from regulatory agencies and other standard
conditions, including product quality. The parties do not foresee any significant regulatory
obstacles, as the product has a low-risk classification, and most of the documentation is already in
place. Intellego will have to continue to invest in the market together with Likang during the time
period up until market launch and afterwards. The volumes will be achieved over a five-year
period, with volumes increasing progressively over time. The sales launch is projected to occur in
late 2025.
Zhongyou Medical (Likang) is a wholly owned subsidiary of Jiangsu Yuyue Medical Equipment and
Supply Co., Ltd, which is listed on the Shenzhen Stock market, a leading distributor of a variety of
disinfectant products into more than 3000 hospitals in China nationally.
Yuwell medical, with full name of Jiangsu Yuyue Medical Equipment and Supply Co., Ltd. has
established 12 R&D centers and 9 production bases in Shanghai, Shenzhen, Nanjing, Suzhou,
Danyang, Tibet, the Netherlands, Germany, Italy, and other places, forming a complete global
R&D, production, marketing, and service network that serves more than 300,000 medical
institutions worldwide and covers 131 countries and regions, benefitting 300 million households

10 tykkäystä
97

Eihän tässä ehdi edellistäkään diiliä kunnolla käsittelemään kun pusketaan jo uutta. Ellei ole joku vanha tieto uudella tiedotteella. Mutta vaihteeksi sentään USA eikä Kiina.

Intellego has initiated negotiations with one of the world’s largest companies in the pharmaceutical consumables and production sector. This US-based company has over 10,000 employees and operates in more than 150 countries. It is a subsidiary of one of the world’s leading pharmaceutical groups, which employs over 80,000 people globally.

The company has spent the past nine months evaluating Intellego’s UV LED dosimeters and the market, yielding positive results. The aim of this collaboration is to launch Intellego’s UV LED dosimeters, and potentially other dosimeter products, on the global market which has an estimated value of EUR 2 billion per year.

The launch is planned for 2025, with sales expected to increase progressively over time.

10 tykkäystä
101

28.11 Q3 ulkona. Parin päivän päästä nähdään missä mennään. Viimeisimmät diilit ei toki tässä rapsassa näy kun realisoituvat vasta 2025 -2026

1 tykkäys
102

Q3 ulkona.
Kassavirta ilkeästi negatiivinen, vaikka saatavia onkin Q3:n jälkeen saatu takaisin ja loputkin luvattu tämän vuoden puolella. Saatavat isoilta asiakkailta. En osaa kyllä yhtään ajatella mitä markkinat tästä ajattelevat. Yhtiön omiin kasvuennusteisiin roima korotus. Anteja ei tarvita ja liikevaihdossa pysyttiin luvatussa 70miljoonassa ja se ylitettiin yli 5%:lla. Vuoden tulos tällä hetkellä 66milj.

Intellego Quarterly Report 1 July to 30 September 2024

Summary of the period 1 July to 30 September 2024

  • Net sales TSEK 74,402 (43,380)
  • Cash flow from current operations TSEK -4,970 (5,762)
  • Profit after financial items TSEK 17,020 (13,380)
  • Profit after tax TSEK 12,300 (12,307)
  • Earnings per share, before dilution SEK 0,44 (0,47)

The entire quarterly report is available at: Rapporter - Intellego Technologies

A Message from the CEO
Intellego’s journey of growth continued during Q3 and we are on track to achieve our goal of reaching over 300 million SEK in revenue with EBIT of over 110 million SEK in 2024. Cashflow for the full year continues to improve and the company currently has approximately 50 million SEK in short term liquid assets where most of it is cash in the bank, which is expected to grow until the end of the year. These funds will be sufficient for Intellego to fully finance its foreseeable future growth. In addition, several projects are now being launched which will provide significant revenue increase in 2025 why Intellego hereby update its long-term financial goals to 2 billion SEK in revenue and 600 million SEK in EBIT in the next 3 to 5 years, a 100% increase from Intellego’s last long term financial goals.

Revenue in Q3 was in line with expectations but EBIT was lower than we hoped due to 5 million SEK in increased external costs, the fine from Nasdaq of 2,2 million SEK and depreciation on capital equipment of almost 5 million SEK. Gross margin for the group was also lower due to sales of capital equipment. The EBIT level and gross margin are expected to increase from these Q3 levels based on, e.g. dosimeter sales will follow equipment sales plus we have several major dosimeter projects that are being started towards the end of the year. Operational cash flow was also lower than expected which was caused by late payments from two customers amounting to a value of approximately 20 million SEK. The company have now received full payment from one of these customers and the other one have expressed that the payment shall arrive to Intellego before the end of this year. Furthermore, from the 187 million SEK in revenue from 2023, approximately 90% of those have been paid to today’s date which shows that receivables are turned into cash, but it also shows that the company has more work to do on shortening the payment times, especially with our largest customers. This work is ongoing and takes time but it is moving in the right direction. As the existing receivables are mainly with larger customers its possible for Intellego credit secure its receivables through Intellego’s new financing structure, that eliminates the risk in the receivables, which will be mentioned more in detail below. As Intellego now also approximately 50 million SEK in short term liquid assets and growing, Intellego is in a good position to finance its future growth without having to raise external capital.

7 tykkäystä
103

Kassavirrasta kun poistaa käyttöpääoman muutokset niin ei näytä enää lainkaan pahalta: Cash flow from current operations before changes in working capital 22826 vs. 14850.

Kasvua ~ 54%.

Liiketoiminta kasvaa
Kassavirta positiivinen ja kasvussa
Näkymät suorastaan loistavat
Nykyinen arvostus edelleen todella matala

Näyttää jopa liian hyvältä joten jotakin täytyy olla pielessä :sweat_smile:
En kyllä keksi mikä…

Ainoa harmituksen aihe että en ostanut 30 kruunun tienoilla lisää, halusin nähdä osavuosituloksen. Nyt jos dippaa tuon Q3 kassavirran vuoksi niin en epäröi toista kertaa lisätä painoa edelleen…

6 tykkäystä
104

Eipä tätä nyt viitsi kevennellä kun sisäpiiri lappaa osaketta taskuihinsa. Joutui pitämään hetken tauon hiljaisen ajan takia. Rapsa ulkona niin ei muuta kuin kättä taskuun.

Ei mitään nappikauppaa

“Claes Lindahl har i ett antal affärer köpt totalt drygt 133.000 aktier i Intellego, där han är vd. Köpen gjordes till kurser mellan 37:15 och 41:39 kronor, enligt Finansinspektionens insynsregister.”

6 tykkäystä
105

Tämän aamun nousun syy ?

Moving closer to market launch - positive feedback from regulatory authorities in China

On the 18th of November, Intellego announced an expanded collaboration with Likang for the Chinese disinfection market. Since then, Intellego and Likang have met with regulatory authorities such as China’s equivalent to the CDC (Centers for Disease Control and Prevention), infection control experts, and key opinion leaders, who all have given positive feedback. This further confirms that the product launch in China is expected to take place at the end of 2025, with full completion of the compliance process at that time, if not earlier.

2 tykkäystä
106

Olisin itsekin saattanut laukaista warret, jos niitä olisi.

Intellego’s Managing Director, Asia Pacific David Chen exercises warrants and Intellego receives approximately SEK 2.2 million

Intellego Technologies AB (publ) (“Intellego” or the “Company”) today announces the outcome of the exercise of warrants of series TO 2021/2024C (the “Warrants”), which were issued during 2021, by resolution of the Extraordinary General Meeting held on 23 December 2021. 87,000 Warrants have been exercised by Intellego’s Managing Director, Asia Pacific David Chen for the subscription of 87,000 shares. The subscription price per exercised Warrant amounted to SEK 25.12. Through the exercise of the Warrants, Intellego receives approximately SEK 2.2 million before issuing costs.

Background
At the Extraordinary General Meeting in Intellego held on 23 December 2021 it was resolved on a directed issue of a total of 102,000 warrants of series TO 2021/2024C, of which 87,000 were allocated to the Company’s Managing Director, Asia Pacific David Chen. Each Warrant gave the holder right to subscribe for one share in the Company during the period from and including 1 December 2024 up to and including 15 December 2024. The subscription price for the Warrants amounted to SEK 25.12 per exercised Warrant.

Intellego’s Managing Director, Asia Pacific David Chen have exercised 87,000 Warrants, corresponding to approximately 85 percent of the issued Warrants, for the subscription of 87,000 shares at a subscription price amounting to SEK 25.12 per exercised Warrant. Through the exercise of the Warrants Intellego receives approximately SEK 2.2 million before issuing costs.

Number of shares, share capital and dilution
Through the exercise of the Warrants the number of shares in Intellego increases by a total of 87,000 shares, from 29,317,476 shares to 29,404,476 shares and the share capital increases by approximately SEK 3,107.14, from approximately SEK 1,047,052.73 to approximately SEK 1,050,159.87. The exercise of the Warrants entails a dilution of approximately 0.3 percent of the total number of shares and votes.

2 tykkäystä
107

Hai solutionin tuote fda:lla ensi vuonna käsittelyssä.
FDA submission in January 2025, with approval expected by mid-2025.

Usability testing for HAI Solutions’ products has received overwhelmingly positive feedback, confirming the strong demand for innovative disinfection solutions. Multiple U.S. hospitals, collectively processing over 1 million port protector caps annually per hospital, have expressed significant interest in adopting a UVC-based disinfection cap.

5 tykkäystä
108

IMG_20250109_150704
IMG_20250109_1507041060×1536 149 KB

2 tykkäystä
109

Linkedin postaus jossa taas sivutaan pilvipalvelu+dosimeter scannausta. Tästä selvästi on terveydenhoitopuolella jo testikäyttöä.

"This cutting-edge technology combines cloud-based solutions, AI integration, SaaS capabilities, and Dosimeter scanning for validation.
All Certified and cyber security protected!

Best solution for surgery/operating rooms, patient rooms, corridors, clinics, diagnostics, labs, food production etc.
Stay ahead with this breakthrough in healthcare decontamination"

1 tykkäys
110
1 tykkäys
111

Intellegon uvc puhdistuslaittevalmistaja Yuvion uusi johtaja valittu. Linkedin jutussa kertoilee että tavoitteena 500 laitteen toimitus markkinoille ensi vuoden aikana.

3 tykkäystä
112

Intellegon ja Henkelin shoppari lopulta allekirjoitusta vaille valmis.

Intellego and Henkel announce global collaboration for the PSA market

tänään klo 15.00 ∙ MFN

Intellego and Henkel have been working together for several years on a project within the global UV curing PSA market (Pressure Sensitive Adhesives). The collaboration is progressing well, and the parties are currently discussing an exclusive global commercial agreement, aiming to be signed in the near future.

4 tykkäystä